We have previously shown that adipsin (complement factor D, CFD), an adipokine secreted predominantly from adipocytes, enhances proliferation and CSC properties of breast cancer patient-derived xenograft (PDX) cells; and this effect is mediated by C3a, a downstream product of adipsin, produced in the alternative pathway of the complement system [11]. Here, CFD is linked to breast carcinoma.